Nalmefene

Generic Name
Nalmefene
Brand Names
Opvee, Revex, Selincro
Drug Type
Small Molecule
Chemical Formula
C21H25NO3
CAS Number
55096-26-9
Unique Ingredient Identifier
TOV02TDP9I
Background

Nalmefene, a 6-methylene analogue of naltrexone, is an opioid receptor antagonist. It acts as an antagonist at the mu (μ)-opioid and delta (δ)-opioid receptors and a partial agonist at the kappa (κ)-opioid receptor.
...

Indication

Nalmefene oral tablet is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL), without physical withdrawal symptoms and who do not require immediate detoxification. Nalmefene should only be prescribed in conjunction with continuous psychosocial support focused on treatment adhe...

Associated Conditions
Alcohol Dependency, Opioid Overdose
Associated Therapies
-
Clinical Trials
Related News

TH104 for the Treatment of Pruritus in Primary Biliary Cholangitis

Phase 2
Not yet recruiting
Conditions
Pruritus
Primary Biliary Cholangitis
Interventions
Drug: Nalmefene
Drug: Placebo
First Posted Date
2024-12-13
Last Posted Date
2024-12-17
Lead Sponsor
Tharimmune Inc
Target Recruit Count
40
Registration Number
NCT06733519

An Evaluation of The Absolute Bioavailability of TH104

Phase 1
Active, not recruiting
Conditions
Healthy
Interventions
Drug: Nalmefene
First Posted Date
2024-01-10
Last Posted Date
2024-02-13
Lead Sponsor
Tharimmune Inc
Target Recruit Count
20
Registration Number
NCT06198686
Locations
🇺🇸

Novum Pharmaceutical Research Services, Las Vegas, Nevada, United States

NAlmefene Versus Placebo in Addition to Treatment as Usual on Craving in Behavioural Addictions

Phase 3
Recruiting
Conditions
Behavioural Addiction
Interventions
Drug: Nalmefene
Drug: Placebo
First Posted Date
2022-09-14
Last Posted Date
2023-11-09
Lead Sponsor
Nantes University Hospital
Target Recruit Count
266
Registration Number
NCT05540288
Locations
🇫🇷

CHU de Besançon, Besançon, France

🇫🇷

CHU de Clermont Ferrand, Clermont-Ferrand, France

🇫🇷

CH de La Rochelle, La Rochelle, France

and more 8 locations

Pharmacokinetic Evaluation of Intranasal Nalmefene

First Posted Date
2021-02-18
Last Posted Date
2024-08-13
Lead Sponsor
Opiant Pharmaceuticals Inc
Target Recruit Count
68
Registration Number
NCT04759768
Locations
🇺🇸

Worldwide Clinical Trials, San Antonio, Texas, United States

Effect of Nalmefene on the Quality of Resuscitation in Patients Under General Anesthesia

Phase 4
Recruiting
Conditions
Resuscitation
Interventions
Drug: normal Saline
Drug: Nalmefene
First Posted Date
2021-01-19
Last Posted Date
2022-10-06
Lead Sponsor
RenJi Hospital
Target Recruit Count
520
Registration Number
NCT04713358
Locations
🇨🇳

The First Affiliated Hospital of Guangxi Medical University, Guangxi, Guangxi, China

🇨🇳

Renji Hospital, Shanghai, Shanghai, China

🇨🇳

Shanghai Tong Ren Hospital, Shanghai, Shanghai, China

and more 1 locations

Patient Driven Recovery With Nalmefene and Coaching

Phase 1
Completed
Conditions
Harmful; Use, Alcohol
Opioid-use Disorder
Interventions
Drug: Nalmefene
First Posted Date
2017-09-12
Last Posted Date
2021-01-22
Lead Sponsor
Yale University
Target Recruit Count
10
Registration Number
NCT03279562
Locations
🇺🇸

Yale University, Department, New Haven, Connecticut, United States

St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Nalmefene

First Posted Date
2017-09-12
Last Posted Date
2020-08-24
Lead Sponsor
Boston Medical Center
Target Recruit Count
11
Registration Number
NCT03278886
Locations
🇷🇺

First St. Petersburg Pavlov State Medical University, St. Petersburg, Russian Federation

Pharmacokinetic Evaluation of Nalmefene Administered Intranasally to Healthy Volunteers

Phase 1
Completed
Conditions
Opioid-Related Disorders
Interventions
Drug: Nalmefene
First Posted Date
2017-04-26
Last Posted Date
2018-03-26
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Target Recruit Count
14
Registration Number
NCT03129347
Locations
🇺🇸

Vince and Associates Clinical Research, Overland Park, Kansas, United States

Effect of Dexmedetomidine Combined With Low-dose Nalmefene on Preventing Remifentanil-induced Postoperative Hyperalgesia

First Posted Date
2017-03-30
Last Posted Date
2021-08-03
Lead Sponsor
Tianjin Medical University General Hospital
Target Recruit Count
150
Registration Number
NCT03096730
Locations
🇨🇳

Tianjin Medical University General Hospital, Tianjin, Tianjin, China

Nalmefene, Baclofen and Impulsivity in Subjects With Alcohol Use Disorder and Healthy Control Subjects

First Posted Date
2017-01-27
Last Posted Date
2020-10-29
Lead Sponsor
Prof. Daniele Zullino
Target Recruit Count
37
Registration Number
NCT03034408
Locations
🇨🇭

Service d'Addictologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy